Fosamax-Related Osteonecrosis of the Jaw: Understanding the Biological Plausibility

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Communication to Occupational Exposure Awareness

The legacy of general health and science communication has long emphasized the importance of informed decision-making and awareness of potential risks associated with medical interventions. Within this broad context, public health messaging has historically focused on the benefits and side effects of pharmaceutical treatments, encouraging patients and providers to weigh therapeutic outcomes against possible adverse events. This foundational approach to health literacy has created a baseline understanding that certain medications, while effective for their intended purposes, may carry unintended consequences that warrant careful monitoring. Transitioning from this general health perspective to a more specific occupational exposure concern requires a shift in focus. In mass production environments, workers may encounter pharmaceutical compounds or their precursors during manufacturing, packaging, or quality control processes. The presence of such substances in the workplace introduces a distinct set of considerations, as occupational exposure pathways differ from those of therapeutic use. For instance, inhalation of airborne particles or dermal contact with active ingredients could lead to systemic absorption, potentially mimicking or altering the risk profile observed in clinical populations. This pivot from patient-centered health information to industrial hygiene underscores the need for rigorous exposure assessment and protective measures. By applying the same principles of risk awareness that guide general health communication, occupational health professionals can better evaluate and mitigate potential hazards inherent in pharmaceutical production settings.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the general principles of risk awareness, we now focus on a specific pharmaceutical agent: Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption by osteoclasts, which reduces bone turnover. While this effect is beneficial for increasing bone mass and reducing fracture risk, it has been associated with a rare but serious adverse event: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves pain, swelling, infection, and exposed bone that fails to heal over a period of weeks to months. Diagnosis is based on clinical examination and imaging, with the exclusion of metastatic disease or other causes of jaw necrosis.

Biological Plausibility of Fosamax-Induced ONJ

The biological plausibility linking Fosamax to ONJ is supported by several mechanistic pathways. Bisphosphonates, including alendronate, accumulate in bone tissue, particularly at sites of high bone turnover such as the jaw. The jawbone undergoes constant remodeling due to mechanical stress from chewing and the presence of teeth. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). This research indicates that bisphosphonate treatment alters the mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These changes can impair the bone's ability to remodel and repair itself, particularly after invasive dental procedures. The primary mechanistic pathway involves the suppression of osteoclast activity. Osteoclasts are essential for bone resorption and remodeling, which is necessary for healing after tooth extraction or infection. By inhibiting osteoclast function, Fosamax reduces the removal of necrotic bone and impairs the formation of new bone, leading to non-healing lesions. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone, and can alter the immune response, increasing susceptibility to infection.

Risk Factors and Warning Adequacy

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning about osteonecrosis of the jaw. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of bisphosphonate use to minimize ONJ risk, and it states that the optimal duration of use has not been determined (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations and Temporal Relationship

Causation considerations for affected patients involve assessing the temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship, as the condition improves with drug cessation and recurs with re-exposure. However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event that may not be detected in clinical trials. The timeline between exposure and documented harm can vary widely. ONJ may develop after months to years of bisphosphonate use, and the risk increases with longer duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In some cases, symptoms can appear as early as one day after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), though this is less common. The condition is often triggered by dental procedures, which can precipitate the onset of symptoms in patients who have been on bisphosphonate therapy for some time.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the biological mechanism linking Fosamax to osteonecrosis of the jaw?

Fosamax (alendronate) suppresses osteoclast activity, which is essential for bone remodeling and healing. By inhibiting osteoclasts, Fosamax reduces the removal of necrotic bone and impairs new bone formation, particularly in the jawbone which undergoes constant remodeling. Additionally, bisphosphonates may have anti-angiogenic effects and alter immune response, increasing infection susceptibility. These changes can lead to non-healing lesions after dental procedures (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the known risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. The risk increases with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How does the prescribing information for Fosamax address the risk of ONJ?

The Fosamax label includes a specific warning that ONJ has been reported in patients taking bisphosphonates, including Fosamax. It notes that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures. However, the label states that the optimal duration of use to minimize ONJ risk has not been determined (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.